Osteocyte RANKL: new insights into the control of bone remodeling - PubMed (original) (raw)

Review

Osteocyte RANKL: new insights into the control of bone remodeling

Jinhu Xiong et al. J Bone Miner Res. 2012 Mar.

Abstract

The idea that osteoblasts, or their progenitors, support osteoclast formation by expressing the cytokine receptor activator of NFkB ligand (RANKL) is a widely held tenet of skeletal biology. Two recent studies provide evidence that osteocytes, and not osteoblasts or their progenitors, are the major source of RANKL driving osteoclast formation in cancellous bone. The goal of this review is to highlight the results of these new studies and discuss their implications for our understanding of bone remodeling.

Copyright © 2012 American Society for Bone and Mineral Research.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Model depicting mechanisms by which osteocytes may independently control bone resorption and bone formation. Osteoclasts (OCs) and osteoblasts (OBs) within a cancellous BMU are shown as being derived from precursors (pOC and pOB). Osteocytes alter the rate of bone remodeling by controlling osteoclast formation via production of RANKL. On the other hand, osteocytes also control the balance between formation and resorption by regulating osteoblast formation via production of sclerostin. Sclerostin may have additional actions such as stimulation of RANKL expression by osteocytes.

References

    1. Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26:229–238. - PMC - PubMed
    1. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–1315. - PMC - PubMed
    1. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003;278:1998–2007. - PubMed
    1. Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577–589. - PMC - PubMed
    1. Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) Hum Mol Genet. 2001;10:537–543. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources